ScreenerHero

AURA Aura Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · aurabiosciences.com
6.460USD+4.70%Mkt Cap: 669.93M $P/E: —

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like par…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap669.93M USD
Enterprise Value332.61M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-106.19M USD
Revenue/Share—
Last Price6.460 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.04
PEG—
EV/EBITDA-2.43
EV/Revenue—
P/S—
P/B2.02
EPS (TTM)-1.74
EPS (Forward)-2.03
52W Range
4.73036% of range9.535
52W High9.535 USD
52W Low4.730 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-77.56%
ROA-62.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.74M USD
CapEx (TTM)447.00K USD
FCF Margin—
FCF Yield-8.41%
Net Debt-307.25M USD
Net Debt/EBITDA2.24
Balance Sheet
Debt/Equity0.13
Current Ratio16.82
Quick Ratio16.65
Book Value/Sh3.05 USD
Cash/Share3.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)16.60 USD
Upside (mean)+157.0%
Target Range12.00 USD – 23.00 USD
12.00+157.0% to mean23.00
# Analysts5
Ownership
Shares Out.103.70M
Float74.64M
Insiders2.43%
Institutions95.45%
Short Interest
Short Ratio8.7d
Short % Float6.84%
Short % Out.6.80%
Shares Short7.05M
Short (prev mo.)6.16M
Technical
SMA 507.124 (-9.3%)
SMA 2006.636 (-2.7%)
Beta0.41
S&P 52W Chg16.45%
Avg Vol (30d)969.09K
Avg Vol (10d)917.05K
Technical Indicators
RSI (14)46.3
MACD-0.2745
MACD Signal-0.2983
MACD Hist.+0.0237
BB Upper7.347 USD
BB Middle6.473 USD
BB Lower5.599 USD
BB Width27.00%
ATR (14)0.3082 USD
Vol Ratio (20d)0.76x